BTG3 and systemic lupus erythematosus: This observation is surprising because ANA was previously thought to be persistently present in most if not all SLE patients (22, 23), and spurs several questions around ANA, such as the possibility of ANA positive SLE patients (so called immune-active) may respond to some therapies differently from ANA negative patients.